

# Greater Manchester Joint Formulary & RAG/DNP list change log

17 January 2023

The list below includes changes made in the last 12 months. For information on older updates, contact [nuth.enquiries.gmmmg@nhs.net](mailto:nuth.enquiries.gmmmg@nhs.net)



Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
17/01/2023	1	1.2	Medicines added to formulary to reflect newly approved hypersalivation guidance: hyoscine tablets and patches, atropine eye drops, glycopyrronium oral solution.	Y	Y	7.6
17/01/2023	6	6.1.1.1	Insuman Comb 50 removed from formulary - product discontinued	n/a	Y	9.14
17/01/2023	6	6.4.1	Section updated to reflect HRT guidance: addition of Bijuve, Elleste Duet Conti, tibolone, Estradot, Oestrogel, Sandrena, Lenzetto, norethisterone, Provera, Utrogestan oral capsules, Mirena IUS	n/a	Y	9.14
17/01/2023	6	6.4.2	Section updated to reflect HRT guidance: testosterone for low sexual desire in post-menopausal women updated to GREEN (specialist advice), and remains GREY	Y	Y	9.14
17/01/2023	7	7.2.1	Section updated to reflect HRT guidance: Gynest, Ortho-Gynest & Vagifem removed; Ovestin, Imvaggis, Vagirux, Estring added.	n/a	Y	7.2
17/01/2023	10	10.1.3	Links to NICE TA711 (guselkumab for psoriatic arthritis) removed and replaced with links to updated NICE TA815	Y	Y	7.9
17/01/2023	11	11.8.2.3	NICE TA820, brolocizumab for diabetic macular oedema, added	Y	Y	5.4
17/01/2023	13	13.5.3	Abrocitinib, tralokinumab & upadacitinib added as RED drugs, in line with NICE TA814	Y	Y	6.4
19/12/2022	1	1.3.1	Famotidine 20mg & 40 mg tablets added to formulary as GREEN as first choice H2 receptor antagonist replacing ranitidine.	Y	Y	7.5
19/12/2022	2	2.12	Icosapent ethyl added as GREEN (specialist advice) as per NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides <a href="https://www.nice.org.uk/guidance/ta805">https://www.nice.org.uk/guidance/ta805</a> , ?note that pathway is pending	Y	Y	7.12
19/12/2022	2	2.12	Black triangle added against inclisiran	n/a	Y	7.12
19/12/2022	4	4.4	Modafinil RAG status updated to GREEN (following specialist initiation) following publication of information for primary care prescribers.	Y	Y	9.13
19/12/2022	4	4.2.1	RAG status for lurasidone updated to AMBER following publication of updated shared care protocol for atypical antipsychotics	Y	Y	9.14
19/12/2022	4	4.2.1	Paliperidone MR tablets added to formulary with AMBER status, in line with updated SCP	Y	Y	9.14
19/12/2022	4	4.8.1	Fenfluramine added as a RED drug as per NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome	Y	Y	9.14
19/12/2022	8	8.2	Imlifidase added as a RED drug as per NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	Y	Y	12.5
19/12/2022	9	9.1.3	Roxadustat added as RED as per NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease	Y	Y	6.4
19/12/2022	9	9.2.1.1	Sodium zirconium cyclosilicate and patiromer sodium for hyperkalemia both updated to AMBER following publication of shared care protocols.	Y	Y	6.4
19/12/2022	10	10.1.3	Risankizumab added as RED per NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	n/a	Y	7.8
19/12/2022	RAG	RAG	Metolazone - removed reference to unlicensed product, and added recommendation for brand name prescribing.	Y	n/a	n/a
19/12/2022	RAG	RAG	Add setmelanotide as RED as per NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency <a href="https://www.nice.org.uk/guidance/hst21">https://www.nice.org.uk/guidance/hst21</a>	Y	n/a	n/a
16/12/2022	1	1.5.2	Budesonide MR - amended to remove advice on specialist initiation, and add MGSG decision "counselling on the safe use of steroids should be provided by the specialist"	Y	Y	7.4

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
16/12/2022	3	3.4.2	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management	n/a	Y	8.6
16/12/2022	6	6.1.2.3	Tirzepatide - statement added to clarify that tirzepatide has not considered by GMMMG pending NICE and shouldn't be used	Y	Y	9.13
16/12/2022	13	13.5.3	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management	n/a	Y	6.3
24/11/2022	1	1.5	Filgotinib added as RED for moderately to severely active ulcerative colitis, in line with NICE TA792	Y	Y	7.3
24/11/2022	1	1.5	Black triangle against Amgevita (adalimumab) removed; no longer applies to this product.	n/a	Y	7.3
24/11/2022	1	1.4.2	Teduglutide added as a RED drug, in line with NICE TA804	Y	Y	7.3
24/11/2022	2	2.3.2	Mexiletine for life-threatening ventricular arrhythmias added as RED	Y	Y	7.11
24/11/2022	4	4.3	Links to superseded NICE guideline CG90 removed and replaced with link so NG222: Depression in adults.	n/a	Y	9.12
24/11/2022	4	4.4	MHRA DSU link added: Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations	n/a	Y	9.12
24/11/2022	4	4.1.1	Adaflex added to formulary as first choice melatonin product.	Y	Y	9.12
24/11/2022	8	8.2.4	Black triangle for canakinumab removed; no longer applies to this product	n/a	Y	12.4
24/11/2022	8	8.2.4	Diroximel fumarate added as RED, in line with NICE TA794: diroximel fumarate for treating relapsing–remitting multiple sclerosis		Y	12.4
24/11/2022	8	8.2.4	Link to NHSE commissioning policy multiple sclerosis updated	n/a	Y	12.4
24/11/2022	8	8.2.4	Link added to NICE NG220: Multiple sclerosis in adults: management	n/a	Y	12.4
24/11/2022	10	10.1.4	Link to superseded NICE TA164 (febuxostat for gout) removed and replaced with links to NICE NG219: Gout diagnosis and management.	n/a	Y	7.7
24/11/2022	11	11.8.2.2	Ranibizimab biosimilar added to formulary as first choice VEGF-A for NICE-approved indications	n/a	Y	5.3
24/11/2022	11	11.8.2.2	Faricimab added as RED in line with NICE TA799 & TA800	Y	Y	5.3
07/11/2022	2	2.5.5.1	Dapagliflozin for CKD added as Green, in line with NICE TA775	Y	Y	7.10
07/11/2022	2	2.8.2	Edoxaban made first choice DOAC for atrial fibrillation only; formulary positions of the DOACs unchanged in other indications. Link added to GMMMG DOAC statement.	n/a	Y	7.10
07/11/2022	6	6.1.2.3	Sitagliptin moved to first choice DPP4 inhibitor; alogliptin moved to "alternative"	n/a	Y	9.12
07/11/2022	6	6.6.2	Romosozumab for severe osteoporosis added as RED, as per NICE TA791	Y	Y	9.12
07/11/2022	11	11.8.1	Simple eye ointment added to DNP list, criterion 3	Y	Y	5.2
07/11/2022	RAG		Entry for levetiracetam amended to clarify the RAG status applies to oral formulations, as per formulary	Y	n/a	n/a
14/10/2022	6	6.4.1.2	Micronised progesterone vaginal capsules (utrogestan) amended to GREEN (following specialist initiation), in line with CRG decision	Y	Y	9.11
26/09/2022	2	2.5.5.1	Empagliflozin for heart failure added as Green (specialist advice), in line with NICE TA773	Y	Y	7.9
26/09/2022	3	3.1.1	MHRA DSU link added: Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists	n/a	Y	8.5
26/09/2022	4	4.3	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to antidepressant section	n/a	Y	9.11
26/09/2022	4	4.4	Pitolisant for obstructive sleep apnoea added to DNP list (criterion 1)	Y	Y	9.11
26/09/2022	4	4.4	Solriamfetol for obstructive sleep apnoea added to DNP list (criterion 1)	Y	Y	9.11
26/09/2022	4	4.1.1	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to z-drug section	n/a	Y	9.11
26/09/2022	4	4.1.2	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to benzodiazepine section	n/a	Y	9.11

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
26/09/2022	4	4.7.2	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to opioid section	n/a	Y	9.11
26/09/2022	4	4.7.3	Link to NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults added to neuropathic pain section	n/a	Y	9.11
26/09/2022	4	4.7.4.2	MHRA DSU link added: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure	n/a	Y	9.11
26/09/2022	4	4.8.1	Link to superseded NICE guidance CG137 removed and replaced with link to NG217 Epilepsies in children, young people and adults	n/a	Y	9.11
26/09/2022	4	4.8.1	MHRA DSU link added: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure	n/a	Y	9.11
26/09/2022	5	5.3	Nirmatrelvir / ritonavir (Paxlovid) added to formulary as RED	Y	Y	7.4
26/09/2022	6	6.1.2.3	Lixisenatide removed from formulary following discontinuation of 10mcg and initiation packs. Note added that patients who are clinically stable may continue and should not be switched without clinical reason.	Y	Y	9.9
26/09/2022	6	6.4.1.2	Micronised progesterone vaginal capsules added to formulary as GREEN for management of miscarriage, in line with NICE NG126	Y	Y	9.9
26/09/2022	6	6.6.2	Romosozumab for severe osteoporosis added as RED, as per NICE TA791	Y	Y	9.9
26/09/2022	8	8.3.4.2	Goserelin & leuprorelin added as AMBER for male breast cancer, with link to updated shared care protocol	n/a	Y	12.3
26/09/2022	10		Link to NG191 (COVID-19) added against baricitinib.	n/a	Y	7.6
26/09/2022	13	13.2	Emollients updated to align with primary care dermatology emollient ladder. First choice and alternatives changed in all categories	n/a	Y	6.2
26/09/2022	13	13.9	Minoxidil foam added to DNP list and note added to clarify that minoxidil cream, lotion, ointment & solution are included in Drug Tariff part XVIII ("black list")	Y	Y	6.2
26/09/2022	13		Link to NG191 (COVID-19) added against baricitinib.	n/a	Y	6.2
26/09/2022	DNP		Anti-reflux milks added to DNP list, with link to CMPA policy	Y	n/a	n/a
26/09/2022	RAG		Elosulfase alfa RAG entry updated to replace link to superseded NICE HST2 with NICE HST19	Y	n/a	n/a
26/09/2022	RAG		Pegcetacoplan added as RED for treatment of PNH, in line with NICE TA778	Y	n/a	n/a
26/09/2022	RAG		Atidarsagene autotemcel added as RED, in line with NICE HST18	Y	n/a	n/a
26/09/2022	RAG		Selumetinib added as RED, in line with NICE HST20	Y	n/a	n/a
26/09/2022	RAG		Phenazone + lidocaine ear drops added to paediatric RAG list as GREEN, in line with NICE NG91	Y	n/a	n/a
05/08/2022	6	6.4.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	9.9
05/08/2022	7	7.2.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	7.1
27/07/2022	2	2.12	Wording updated to indicate that "An NHSE/NHS Digital tool to aid identification of eligible patients is available for some primary care clinical systems (EMIS / SystemOne). A GM Case Record finding tool will be available from Health Innovation Manchester shortly."	Y	Y	7.8
27/07/2022	2	2.9	Links to NICE guidance and MHRA Drug Safety Updates re-formatted for clarity. Broken links to MHRA DSUs for prasugrel (hypersensitivity reactions, May 2011) and clopidogrel (risk of haemophilia, Dec 2013) corrected. Links to MHRA DSUs for prasugrel (risk of bleeding, Jan 2014) and clopidogrel (omeprazole interaction, April 2010) added.	n/a	Y	7.8
25/07/2022	2	2.12	Following wording now outdated, and has been removed: "The pricing structure agreed by NHSE/I means the NICE approved cost can only be accessed in primary care."	Y	Y	7.7
25/07/2022	4	4.6	Sativex added as RED, in line with NICE NG144: Cannabis-based medicinal products	Y	Y	9.10
22/07/2022	4	4.10.1	Chlordiazepoxide updated to GREEN	Y	Y	9.9

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
22/07/2022	4	4.7.4.2	Links to NICE TA631 (fremanezumab for preventing migraine) removed and replaced to updated NICE TA764.	Y	Y	9.9
22/07/2022	6	6.1.2.2	MHRA DSU link added: Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk	n/a	Y	9.8
22/07/2022	6	6.4.1.1	Added links to information on managing disruptions to HRT supplies.	n/a	Y	9.8
22/07/2022	RAG	10	Tofacitinib for JIA added to paediatric RAG list as RED	Y	n/a	n/a
22/07/2022	RAG	13	Secukinumab for psoriasis added to paediatric RAG list as RED	Y	n/a	n/a
22/06/2022	4	4.7.4	Updated to correct typos and add section on tension headache. Simple analgesics (paracetamol, aspirin, NSAIDs) added as per 4.7.4.1. Amitriptyline added for prophylaxis.	n/a	Y	9.8
17/06/2022	1	1.6.4	Restriction to macrogol 3350 removed, and statement added directing prescribers to choose the most cost-effective macrogol	n/a	Y	7.2
17/06/2022	2	2.5.2	Moxonidine entry updated to GREEN specialist initiation, to clarify position and align with with standard wording. Previously listed as: "Moxonidine (specialist initiation only)"	Y	Y	7.6
17/06/2022	3	3.4.2	Palforzia added to formulary as RED and GREY, only Only for use in people aged 18 and over if treatment started between the ages of 4 to 17, as per NICE guidance.	Y	Y	8.4
17/06/2022	4	4.7	Whole section updated to align with updated GMMMG headache pathway	Y	Y	9.7
17/06/2022	4	4.7, 4.8	MHRA DSU link added: Pregabalin (Lyrica): findings of safety study on risks during pregnancy	n/a	Y	9.7
17/06/2022	4	4.7.4.1	Simple analgesics: ibuprofen (OTC), naproxen (unlicensed) and diclofenac (unlicensed) added	Y	Y	9.7
17/06/2022	4	4.7.4.1	Anti-emetics: prochlorperazine added (5mg tabs unlicensed, 3mg buccal tabs OTC)	Y	Y	9.7
17/06/2022	4	4.7.4.1	Combined preparations: aspirin with metoclopramide added. Paracetamol with isometheptene and paracetamol with codeine and buclizine added to DNP list.	Y	Y	9.7
17/06/2022	4	4.7.4.1	Triptans: zolmitriptan, frovatriptan, and rizatriptan tablets added as alternative choices. Zolmitriptan nasal spray added as first choice nasal, if vomiting restricts oral treatment. Nasal sumatriptan retained as alternative nasal.	Y	Y	9.7
17/06/2022	4	4.7.4.2	Alternative options expanded to include: metoprolol (green, specialist advice), topiramate (green, previously required specialist advice), zonisamide (green, specialist advice), amitriptyline, nortriptyline (green, if intolerant to amitriptyline), candesartan (green), flunarazine (red),	Y	Y	9.7
17/06/2022	4	4.7.4.3	Acute treatment: zolmitriptan nasal spray and oxygen added	Y	Y	9.7
17/06/2022	4	4.7.4.3	Prophylaxis: verapamil added (green, specialist advice)	Y	Y	9.7
17/06/2022	6	6.6.2	MHRA DSU link added: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia	n/a	Y	9.7
17/06/2022	8	8.2.4	Ponesimod for multiple sclerosis added as RED, in line with NICE TA767	Y	Y	12.2
17/06/2022	9	9.1.4	Link added to information on risk of thrombosis on discontinuation of anagrelide	n/a	Y	6.3
17/06/2022	10	10.1.3	Link to NICE TA768 added against upadacitinib	n/a	Y	7.4
17/06/2022	13	13.11.6	Link to NPSA alert on Inadvertent oral administration of potassium permanganate added	n/a	Y	6.1
17/06/2022	13	13.5.2	Brand name and formulation for Calcipotriol 50 micrograms/g, betamethasone dipropionate 0.05% removed from formulary, and replaced with: "Choose the most cost-effective option"	n/a	Y	6.1
17/06/2022	13	13.6.1	Strength of Epiduo gel removed, to align with primary care acne pathway	n/a	Y	6.1
17/06/2022	RAG		Odevixibat added to RAG list as RED, in line with NICE HST17	Y	n/a	n/a
20/05/2022	2	2.12	Bempedoic acid updated to green (specialist advice) from green (specialist initiation)	Y	Y	7.5
20/05/2022	3	3.4.2	Added dupilumab for severe asthma with type 2 inflammation as RED, as per NICE TA751.	Y	Y	8.3
20/05/2022	4	4.4	Solriamfetol for narcolepsy added as a RED drug, as per NICE TA758	Y	Y	9.5
20/05/2022	4	4.4	Modafinil updated to RED pending approval of information for primary care prescribers. Was previously RED pending approval of SCP.	Y	Y	9.5

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
20/05/2022	4	4.7.3	Section updated to reflect updated GMMMG neuropathic pathway. Added nortriptyline (first line alternative) & capsaicin cream (non-oral alternative) and removed gabapentin for trigeminal neuralgia.	n/a	Y	9.5
20/05/2022	4	4.8.1	Cenobamate for focal onset seizures in epilepsy added as Green (following specialist initiation by a tertiary epilepsy service), as per NICE TA753	Y	Y	9.5
20/05/2022	5	5.3	Sotrovimab added as a RED drug as per NICE NG191	Y	Y	7.3
20/05/2022	6	6.1.2.3	Added link to NG203 (chronic kidney disease) to notes on SGLT2 inhibitors.	n/a	Y	9.6
20/05/2022	9	9.1.4	Added fostamatinib for refractory chronic immune thrombocytopenia to DNP list, as per NICE TA759	Y	Y	6.2
20/05/2022	10	10.2	Risdiplam added as a RED drug as per NICE TA755	Y	Y	7.3
20/05/2022	10	10.1.3	Updated belimumab entry to link to updated NICE guidance, NICE TA752	n/a	Y	7.3
20/05/2022	RAG		Liraglutide for obesity in people aged 12-17 added to DNP list.	Y	n/a	n/a
26/04/2022	3	3.2	Corrected typo on Ateectura Breezhaler	n/a	Y	8.1
26/04/2022	3	3.2	Corrected typo on Trixeo Aerosphere	n/a	Y	8.2
21/04/2022	2	2.3.2	MHRA DSU link added: Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision	Y	Y	7.4
21/04/2022	2	2.4 & 2.9	Added link to NICE NG208: heart valve disease presenting in adults	n/a	Y	7.4
21/04/2022	3	3.1 & 3.2	Updated to reflect the GMMMG asthma and COPD management plans	n/a	Y	8.0
21/04/2022	4	4.10.2	Replaced superseded links to NICE NG92 with links to NG209: Tobacco: preventing uptake, promoting quitting and treating dependence	n/a	Y	9.4
21/04/2022	4	4.10.2	Added link to GM tobacco dependency treatment guidelines	n/a	Y	9.4
21/04/2022	6	6.1.2.2	MHRA DSU link added: Metformin in pregnancy: study shows no safety concerns	n/a	Y	9.5
21/04/2022	6	6.1.2.3	Added link to NICE NG28	n/a	Y	9.5
21/04/2022	8	8.2.4	MHRA DSU link added: Cladribine (Mavenclad): new advice to minimise risk of serious liver injury	Y	Y	12.1
21/04/2022	9	9.1	Added crizlanizumab as a RED drug, as per NICE TA743	Y	Y	6.1
21/04/2022	9	9.1.1.2	Updated generic name of Monofer to ferric derisomaltose	Y	Y	6.1
21/04/2022	10	10.1.3	Added link to NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis	Y	Y	7.2
21/04/2022	10	10.1.5	Updated link to GM EUR policy, Hyaluronic Acid injections for Osteoarthritis, to latest version	Y	Y	7.2
21/04/2022	RAG		Added givosiran to RAG list as a RED drug, as per NICE HST16	Y	n/a	n/a
06/04/2022	6	6.1.2.3	Type 1 diabetes indication for dapagliflozin removed, in line with change to licensed indications and MHRA DSU advice.		Y	9.4
11/03/2022	4	4.2.1	Haloperidol 500 microgram tablets added to DNP list (criterion 2)	Y	Y	9.3
11/03/2022	6	6.1.1.1	Insulin aspart biosimilar (Trurapi) added as first-choice rapid acting insulin analogue in diabetes mellitus	Y	Y	9.3
11/03/2022	RAG		Bertralstat added as RED, in line with NICE TA738	Y	n/a	n/a
09/03/2022	2	2.12	Wording added to bempedoic acid to clarify that it should be used in combination with ezetimibe, in line with NICE TA694	Y	Y	7.3
09/03/2022	3	3.7	MHRA DSU link added: Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing	n/a	Y	7.2
09/03/2022	5	5.3	Added molnupiravir as a RED drug, as per NICE NG191	Y	Y	7.2
09/03/2022	5	5.3	MHRA DSU link added: COVID-19 antivirals and pregnancy reporting	Y	Y	7.2
09/03/2022	5	5.4.1	MHRA DSU link added: HCQ & chloroquine risk of CV events & psychiatric reactions	n/a	Y	7.2
09/03/2022	10	10.1.3	MHRA DSU link added: HCQ & chloroquine risk of CV events & psychiatric reactions	Y	Y	7.1
09/03/2022	11	11.8.2.3	MHRA DSU link added: Brolucizumab (Beovu ▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals	Y	Y	5.1

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
23/02/2022	2	2.8.1	Link to NG191: COVID-19 rapid guideline: managing COVID-19 added against low molecular weight heparins	n/a	Y	7.2
23/02/2022	7	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
23/02/2022	11	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	5.0
23/02/2022	13	13.5.3	Bimekizumab added as RED, in line with NICE TA723	Y	Y	6.0
23/02/2022	13	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	6.0
23/02/2022	RAG		Sapropterin entry updated to add link to TA729.	Y	n/a	n/a
22/02/2022	1	1.3	Link to NG201: antenatal care added (contains advice on heartburn)	n/a	Y	7.1
22/02/2022	3	3.1.4	Link to NG202: obstructive sleep apnoea syndrome added (contains advice on managing rhinitis)	n/a	Y	7.2
22/02/2022	4	4.6	Link to NG201: antenatal care added (contains advice on nausea and vomiting in pregnancy)	n/a	Y	9.2
22/02/2022	4	4.7	Duloxetine 90mg & 120mg capsules added to grey list as GREEN drugs. Criterion 2.	Y	Y	9.2
22/02/2022	6	6.1.1.2	Insulin degludec added as GREY and GREEN (specialist initiation)	Y	Y	9.2
22/02/2022	9	9.1 & 9.5	Links to CG157 & NG8 replaced with link to NG203: Chronic kidney disease: assessment and management	n/a	Y	6.0
22/02/2022	9	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	6.0
22/02/2022	12	12.2.1	Link to NG202: obstructive sleep apnoea syndrome added (contains advice on managing rhinitis)	n/a	Y	5.0
22/02/2022	12	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	5.0
22/02/2022	RAG		Isoniazid for TB prophylaxis in renal patients added as GREEN (specialist initiation)	Y	n/a	n/a
22/02/2022	RAG		Dapsone 50 mg & 100mg tablets for PCP prophylaxis added as GREEN (specialist initiation)	Y	n/a	n/a
20/01/2022	4	Various	MHRA DSU link added to formulary in 4.2.1, 4.2.2, 4.2.3: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium	n/a	Y	9.1
19/01/2022	3	3.2	Links to DHSC information on budesonide in COVID-19 deleted and replaced with link to NICE NG191: Managing COVID-19	n/a	Y	7.1
19/01/2022	5	5.3	Ronapreve added as a RED drug	Y	Y	7.1
19/01/2022	6	6.1.1.1	Updated to reflect brand name and specify the insulin for each product, including new brand name for insulin lispro sanofi (Admelog).	n/a	Y	9.1